NCT03983668 2026-03-30
CMP-001 for Relapsed and Refractory Lymphoma
University of Iowa
Phase 1/2 Terminated
Clinical Trials
7 trialsNCT03990961 2026-02-20
Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)
University of Chicago
Phase 2 Terminated
NCT03249792 2025-07-24
MK-2118-001
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT04920383 2024-03-01
NEON-2
Alpine Immune Sciences, Inc.
Phase 1 Terminated
NCT04609579 2024-01-30
Study of SNX281 in Subjects With Advanced Solid Tumors and Lymphoma
Stingthera, Inc.
Phase 1 Terminated
NCT02376699 2023-05-01
Safety Study of SEA-CD40 in Cancer Patients
Seagen Inc.
Phase 1 Terminated
NCT03815682 2022-12-06
RPTR-147 in Patients With Selected Solid Tumors and Lymphomas
Repertoire Immune Medicines
Phase 1 Terminated